News
GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...
2d
TipRanks on MSNGSK’s Promising Study on Belimumab for Systemic Sclerosis Lung DiseaseGlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...
Use of belimumab prior to vs after initiating immunosuppressants was linked to faster OGC tapering and fewer disease flares among patients with SLE.
Although obinutuzumab has not yet received FDA approval in lupus nephritis, findings from a recent survey conducted by ...
Benlysta (belimumab) Analytical Perspective • In-depth Benlysta (belimumab) Market Assessment This report provides a detailed market assessment of Benlysta (belimumab) in Seven Major Markets, i ...
A new study finds that belimumab (Benlysta®) is an effective therapy option for people with cutaneous lupus erythematosus (CLE), a form of lupus that affects the skin. This study highlights that ...
Adding a single cycle of rituximab to belimumab (Benlysta) did not improve disease control for patients with systemic lupus erythematosus (SLE) in comparison with belimumab alone in a phase 3 ...
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stimulator (BlyS)-specific ...
Joan T Merrill, MD, from the Oklahoma Medical Research Foundation in Oklahoma City, and colleagues evaluated the long-term safety profile of belimumab for SLE. Patients were randomized to receive ...
Belimumab was the first FDA-approved medication specifically designed for the treatment of lupus. Learn what you need to know about belimumab. Read the study See More: Research news , Treatment news ...
A 2-year randomized controlled trial has found that belimumab plus standard therapy is superior to standard therapy alone in patients with lupus nephritis, according to data published in the New ...
Belimumab treatment resulted in at least 50% reduction in dsDNA antibodies in 30% of patients, whereas just 17% of subjects treated with placebo experienced this level of reduction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results